Eurofins’ stock price jumped >10% today as its H1 performance and upgraded FY2021 guidance was ahead of market expectations. The core offerings continued to accelerate with the relaxation of restrictions in Q2, while COVID-19-related revenue subsided sequentially. EBITDA margin benefited from accretive COVID-19 volumes and improved utilisation of start-up laboratories. We will raise our financial estimates and target price. However, we will retain our cautious recommendation; also pinned down by
Companies: Eurofins Scientific (ERF:EPA)Eurofins Scientific Societe Europeenne (ERF:PAR)
April was another impressive month for Eurofins with sustained COVID-19-related revenue and accelerated organic growth momentum in the core business, aided by soft comparables. In ytd FY2021 (to April), the group registered organic growth of c.50% yoy. We will revise our financial estimates and target price upwards to incorporate the strong trading update. However, we reaffirm the cautious stance given the expensive valuation.
Eurofins continued its strong showing with 44.3% organic top-line growth in Q1, building on its robust performance in the second half of last year. The share price came under pressure on the back of qoq lower revenue from COVID-19 clinical testing and reagents, whilst core offerings grew at 10% despite the lockdown measures in key geographies. Management maintained its financial guidance for now, but 2021 appears to exceed the financial objectives materially.
Eurofins reported strong FY2020 results, underpinned by robust demand for its COVID-19 testing solutions and continued recovery in core businesses. Pandemic-related opportunities have not only been a boon to the top line but were also accretive to profitability and cash flows. While management largely retained its near-term guidance citing uncertainties, 2021 could be materially higher if demand for testing is maintained. The dividend was also resumed with a proposed €0.68/share, significantly h
Eurofins clocked a better-than-expected performance in Q3 FY20, lifted by its broad COVID-19 testing portfolio and a gradual recovery in the core operations. While the management has left its FY20 and FY21 objectives unchanged, it expects to beat them significantly, as testing demand is likely to be sustained in the near-term. Dividend payments are also expected to resume next year.
Companies: Eurofins Scientific Societe Europeenne
Eurofins Scientific reported strong H1 FY20 results with a resilient top-line and a significant improvement in profit margins. Moreover, the robust FCF generation and equity issuance proceeds helped the group to cut its leverage considerably and move forward its 2.5x net debt / adjusted EBITDA target by a year to the end of FY20. Also, as management expects robust demand for the COVID-19 testing over the coming few months, it has maintained its FY20 revenue and adjusted EBITDA targets.
Eurofins displayed good resilience in Q1 FY20, supported by the food and pharma businesses. Although, the Q2 FY20 performance is likely to be soft, due to the widespread lock-downs, management has maintained its full-year organic growth targets – a robust demand for its COVID-19 testing solutions in the coming months is expected to compensate for the loss in existing businesses. Moreover, the curtailed capex, M&A and operating spending should provide it with sufficient liquidity to navigate thro
A good set of FY19 results from Eurofins Scientific – barring the cyber-attack impact, the company performed satisfactorily against its financial targets. Its progress on the deleveraging front was also noteworthy, besides the curtailed M&A spending. Management remains confident about sustaining the positive momentum in FY20 and FY21. Regarding the Coronavirus, no material effect has been seen yet.
Eurofins reported reassuring top-line growth in Q3 FY19 – the performance was spread across all geographies except for the UK. The growth is likely to be sustained in Q4 FY19, in our opinion. However, what remains concerning about this company is its highly-leveraged position and thin free cash flow. A faulty execution of the improvement plan will hamper investors’ confidence in the stock.
In H1 19, Eurofins clocked a strong top-line performance – though organic growth was slightly behind the street’s estimates, the inorganic expansion nudged it up. More importantly, management estimates the cyber-attack consequences to be insignificant for the company. It has maintained the full-year financial guidance, adjusting for the incident-caused losses. No material change in our estimates.
Eurofins reported a cyber-attack on its IT systems a few days back. The recovery work is ongoing and no unauthorised theft or loss of confidential client data has been reported to date. Although there is no clarity on the financial impact so far, management has alluded to it being ‘material’. We attempt to estimate this loss in a scenario-based model, but conclude that the share price correction was an overreaction.
Despite a tad soft Q1 FY19, Eurofins remains confident in achieving its full-year financial targets. Though clinical diagnostic business’ problems continued in the quarter (regulatory headwinds in the US and France), Food and Environment testing segments remained healthy. No material change in our financial estimates. Our stock recommendation ‘Add’ is likely to be maintained.
While Eurofins reported FY18 profitability ahead of the street’s estimates, investors seemingly were not happy on two fronts: lower organic revenue growth (50bp miss vs full-year target due to Q4) and the deterioration in the group’s leverage position. While we will revise our target price downwards, incorporating a more cautious view on the group’s debt problem, we believe that yesterday’s share price drop was more of an overreaction.
The company reported H1 FY18 results which were in line with our estimates. Recently, the company upgraded its revenue guidance, resulting in a significant jump in the stock price (up 16% in two trading sessions), post which the higher leverage level and significant integration risk wiped out most of these gains. The company successfully raised €550m at 1.38% (vs the average cost of debt of c.3.5%, which should fall further in the near future). We have tweaked our estimates slightly. No change i
The company reported Q1 18 numbers which were below our estimates as well as market consensus. North America, Germany and Belgium & the Netherlands, accounting for half of its revenue (approximately), remained either in line or surpassed its projected growth, whereas France remained subdued and the UK & Ireland recorded negative growth. The company continues with its shopping spree, adding further to its execution risk. We have revised our estimate downward, changing our recommendation from ‘Ad
Research Tree provides access to ongoing research coverage, media content and regulatory news on Eurofins Scientific Societe Europeenne.
We currently have 0 research reports from 0
Full-year results were in line with the trading update of 21 July, with revenues of £31m (-2%), reflecting the impact of COVID-19 on out-patient procedure rates, resulting in 14% and 24% declines in adjusted EBITDA and pre-tax profit, respectively. Lower than expected procedure growth rates and the decision to discontinue non-core (non-chlorine dioxide products) reduces forecast revenues by c.£3m to £33m in FY 2022. However, higher gross profit and tight control of costs (+6%) results in an unch
Companies: Tristel Plc
No Joiners Today.
Cambria Autos has left the AIM following a takeover.
What’s cooking in the IPO kitchen?
Light Science Tech Holdings, the controlled environment agriculture technology and contract electronics manufacturing Group to join AIM. Raising £5m. Expected mkt cap £17.4m. Due 15 Oct.
Harmony Energy Income Trust to join the Specialist Fund Segment of the Main Market raising up to £230m. The Company's investment objective is to provide investors with an attractive and susta
Companies: VRS ORPH SNG MRL EBQ AVG
Companies: WAND SDX SEMP BMK LVCG MOS ACC
TMT Acquisition (TMTA.L) has joined the Main Market (Standard) pursue opportunities to acquire businesses in the technology, media and telecom sector. Raised £5m, mkt cap £5.5m.
NMCN Plc has left the Main Market (Premium) following the appointment of administrators.
What’s cooking in the IPO kitchen?
Harmony Energy Income Trust to join the Specialist Fund Segment of the Main Market raising up to £230m. The Company's investment objective is to provide investors with an attractive
Companies: SEE FST ORCP DNL FDBK 8091 IGP
IXICO has provided an upgraded trading statement for FY21E following its previous update in August 2021. Revenues are now expected to be £9.2m (vs £8.7m previously), broadly in line with FY20A, which we see as a strong result given the pandemic and Huntington's Disease (HD) trials de-scope. EBITDA is expected to be materially ahead of FY20A's £1.3m, supported by strong Q4/21 trading, cost control and positive one-offs. The company has ended FY21 with a strong order book (£18.8m) and cash positio
Companies: IXICO Plc
Today’s prelims are in line with management’s expectations with losses before tax in the period of £30.3m (vs. £29.4m prior year). Post-merger, 4D pharma is clearly a different beast with access to the largest global capital market for Pharma/Biotech, and supported by £25.2m (net) proceeds from corporate activity. The company has cash runway until Q2 2022 and is well placed to successfully execute its clinical development strategy with multiple shots on goal. Primary focus is on MRx0518 with two
Companies: 4d Pharma PLC
Exactly one year ago, the FTSE 100 closed at 5,862, having fallen 100 points on the day, the lowest point since mid-May 2020, due in part, to the strength of sterling vs US$ at $1.34. One year on, the FTSE 100 has risen to 7,119, a rise of 21%, it remains 7% below the peak in January 2020. From an international viewpoint, US and European markets continue to trade at record highs. The US Federal Reserve is close to withdrawing some of its economic support this year as inflation picks up and the e
Companies: AMYT BAG BVC BRSD CLG CML FBD GDWN INV MACF MNZS MIO NRR NSF NBI MATD PREM QFI RUA SCS STVG SUR SNX UPGS VAST VLS
SkinBioTherapeutics has announced it will launch its lead commercial product, AxisBiotix-Ps on World Psoriasis Day, 29 October 2021. To support the launch, the company has begun to receive, and store finished product in the Netherlands (close to its manufacturing partner) ahead of initial launches in the UK and US. Clearly the launch of its first product is a significant step for SkinBioTherapeutics, marking the transition from development company to commercial operation. We are encouraged by th
Companies: SkinBioTherapeutics Plc
Synairgen reported interim results to 30 June in which the adjusted net loss was £32.8m with period-end cash of £46.2m. Substantial pre-commercial progress and manufacturing activities have made in the half, although slower country approvals for trial sites will result in Phase III data readout slipping into Q1 2022. With increasing evidence of the need for a broad-spectrum antiviral delivered to the lungs and recognition that vaccines don’t provide complete protection against hospitalisations d
Companies: Synairgen plc
ANGLE reported an adjusted net loss of £7.2m (+58% vs. -£3.2m), with establishment revenues increasing 26% to £0.3m and costs rising 48% to £8.9m, reflecting the costs of opening its pharma services business and clinical laboratories in the US and UK. Net cash at 30 June was £21.0m, with a further £18.9m (net) placing proceeds after period-end. Evidence of momentum building within pharma services, backed by confirmation of three contract wins and multiple ongoing discussions (some of which are w
Companies: ANGLE plc
*A corporate client of Hybridan LLP
No joiners today.
Conduity Capital has left AIM.
What’s cooking in the IPO kitchen?
Softline the global solutions and services provider in digital transformation and cybersecurity, with its headquarters in London, is considering proceeding with a potential initial public offering of global depositary receipts representing its ordinary shares. The Company is considering applying for admission of the GDRs to the standard listing segm
Companies: SEN SEMP DNORD DNORD FAB MAST SAR CZA MRL
The current situation in the CDMO arena looks a bit like an arms race and Lonza seems to have firm plans to be part of it. The recently updated mid-term guidance is the explanation to do so, in our view. Management is strongly dedicated to staying with the extraordinary high EBITDA margin for the coming years.
Lonza’s hybrid investors day was well attended in Zurich, in which we participated.
Companies: Lonza Group (LONN:VTX)Lonza Group AG (LONN:SWX)
The positive market research results for Eroxon®, released this morning, provides further support for the company’s ongoing partnering efforts. We continue to believe that MED2002 is a differentiated product with significant potential in both prescription and OTC markets, and look forward to further PK data followed by Phase III start in H1 2018.
Companies: Futura Medical plc
The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions yesterday announced it has entered into a partnership with Tabula Rasa HealthCare® (TRHC) (NASDAQ: TRHC), a healthcare technology Company advancing the field of medication safety. Through this initiative, Physiomics' personalised docetaxel model will be integrated into TRHC's market-leading precision dosing solution, DoseMeRx®. Both parties expect positiv
Companies: Physiomics Plc
Samarkand Group Limited, the cross-border eCommerce technology and retail group opening up the world's largest market for brands and retailers, intends to IPO on the Apex Segment Aquis Stock Exchange Growth Market. Admission is targeted for March 2021. Cellular Goods a UK-based provider of premium consumer products based on biosynthetic cannabinoids announced its intention to join the main market (standard) this spring. Target valuation £20m raising c. £8m “to finalise the development and launch
Companies: SYM ABDX NBI BPM TND BRCK PRES ENET CDGP